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9872 | Chem. Sci., 2019, 10, 9872–987LP-1 analogues with prolonged
activity in vivo via signal bias and altered receptor
traﬃcking†
Juliette Fremaux,a Claire Venin,a Laura Mauran,a Robert Zimmer,a Florian Koensgen,c
Didier Rognan, c Stavroula Bitsi,d Maria A. Lucey,e Ben Jones,e Alejandra Tomas,d
Gilles Guichard *b and Se´bastien R. Goudreau *a
The high demand of the pharmaceutical industry for new modalities to address the diversiﬁcation of
biological targets with large surfaces of interaction led us to investigate the replacement of a-amino acid
residues with ureido units at selected positions in peptides to improve potency and generate eﬀective
incretin mimics. Based on molecular dynamics simulations, N-terminally modiﬁed GLP-1 analogues with
a ureido residue replacement at position 2 were synthesized and showed preservation of agonist activity
while exhibiting a substantial increase in stability. This enabling platform was applied to exenatide and
lixisenatide analogues to generate two new ureidopeptides with antidiabetic properties and longer
duration of action. Further analyses demonstrated that the improvement was due mainly to diﬀerences
in signal bias and traﬃcking of the GLP-1 receptor. This study demonstrates the eﬃcacy of single a-
amino acid substitution with ureido residues to design long lasting peptides.Introduction
Backbone modications are a powerful strategy to improve
peptide properties as they generally ameliorate their protec-
tion against proteolysis and therefore their duration of
action.1,2 Such an approach is far from trivial as modifying the
backbone of peptides has generally drastic negative impacts
on binding properties, and consequently, potency. Notewor-
thily aza-amino acids3,4 and b-amino acids5–7 have proved to
be eﬃcient a-amino acid substitutions. Despite the potential
of these approaches, new enabling platforms based on back-
bone modications are still needed to meet the increasingly
demanding requirements of the pharmaceutical industry in
peptide mimicry.8
In the past decade, the incretin glucagon-like peptide-1
(GLP-1) has been largely studied because of its blood glucose
control properties which have led to multiple new treatments
for type 2 diabetes mellitus (T2DM).9 This pharmacologicalt Escarpit, 33607 Pessac, France. E-mail:
Institut Europe´en de Chimie et Biologie, 2
-mail: g.guichard@iecb.u-bordeaux.fr
MR7200 CNRS-Universite´ de Strasbourg,
omics, Imperial College London, London
College London, London W12 0NN, UK
tion (ESI) available. See DOI:
9target remains of considerable ongoing interest as several
studies indicate that GLP-1 analogues could be used for other
important indications such as obesity, major adverse cardiac
events, Alzheimer's disease, or non-alcoholic steatohepatitis
(NASH).9 One particular problem with the use of native GLP-1,
a 29 amino acid natural peptide hormone, is its short in vivo
half-life of 2–3 min.10 Many modications have therefore been
developed to prolong the GLP-1 lasting period, notably,
sequence remodelling and extension (exenatide and lix-
isenatide),11 fatty acid acylation to promote binding to plasma
albumin (liraglutide and semaglutide),11 bonding or fusion to
large proteins (dulaglutide, albiglutide, and efpeglenatide),11
non-natural amino acid replacements,12 side chain cross
linking,13 and more recently a / b-residue replacements,14
thioamide,15 and peptide–oligourea hybrids16 (Fig. 1). A
common modication of GLP-1 analogues is the replacement
of Ala2 with another amino acid (i.e. Gly) to prevent proteo-
lytic cleavage by DPP-4.10,11 However, despite having a glycine
in position 2, exenatide, an FDA approved once-weekly treat-
ment for T2DM, is still susceptible to degradation at its N-
terminus.17 We therefore hypothesize that modifying the
backbone of exenatide might improve its proteolytic stability
and prolong its activity in vivo. However, backbone modi-
cations at the N-terminal part of incretins and other ligands of
class B GPCRs have scarcely been reported15,18–20 which
reects the diﬃculty to mimic the complex network of inter-
actions in the binding pocket of the receptor transmembrane
domain.21This journal is © The Royal Society of Chemistry 2019
Fig. 1 Schematic representation of diﬀerent GLP-1 analogues previ-
ously reported and the present approach (ureidopeptide). GLP-1
analogue modiﬁcations are highlighted in colour; orange: b-amino
acids, purple: macrocycles, blue and yellow: lipidation, green: ureido
residue.
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View Article OnlineHerein we report the utilization of a ureido residue
replacement at position 2 of GLP-1 analogues to improve their
pharmacodynamic properties via selective enhancement of GTable 1 Bioactivity in cAMP production functional assays using HEK293 c
exenatide, lixisenatide and cognate monosubstituted analogues
This journal is © The Royal Society of Chemistry 2019protein-dependent cAMP signalling and altered GLP-1R
traﬃcking.Results and discussion
Peptide design, synthesis and functional assays
Although oligourea foldamers16,22–25 have recently been reported
to be eﬀective a-helix mimics, their constitutive units – ureido
residues – have scarcely been studied in the context of single a-
amino acid replacements.26 Therefore, the ability of GLP-1
analogues with a ureido unit (Xu) (Table 1) at position 2 (e.g.
GLP-1[Au]2 (3)) to interact with the GLP-1 receptor (GLP-1R) was
rst tested in silico by molecular dynamics simulation (see the
ESI†). The cryo-EM structure of GLP-1R (PDB ID: 5VAI),21 which
contains GLP-1 as the ligand, was used both as a starting point
and as a comparator to evaluate the binding mode of GLP-1[Au]2
(3).
As seen from the predicted model, the ureido peptide 3 sits
deeper in the cavity of the transmembrane domain (TMD)
compared to native GLP-1, and its N-terminus is engaged in new
H-bond interactions with the receptor (Fig. 2). In particular, the
terminal amino group of His1 and main chain NHs of the Alau2
unit are H-bonded to Glu364 and Glu387 located in trans-
membrane helices TM6 and TM7, respectively. Moreover, the
salt bridge between Glu3 and Arg190 is supplemented by two
new H-bonds to Tyr145 and Tyr152. On the basis of these
results, we synthesized compound 3 to further investigate toells transfected with GLP-1R and the mouse plasma half-life of GLP-1,
Chem. Sci., 2019, 10, 9872–9879 | 9873
Fig. 2 Predicted structure of the GLP-1R/GLP-1[Au]2 complex
compared to the cryo-EM structure of the GLP-1R/GLP-1 complex. (a
and b) GLP-1 (in orange) in the GLP-1R TMD and an enlarged image (b)
of the N-terminal part (extracted from the cryo-EM structure of the
GLP-1R/GLP-1 complex (PDB 5VAI));21 (c and d) predicted structure of
GLP-1[Au]2 (3) (in blue with Alau2 in green) in the GLP-1R TMD and an
enlarged image (d) of the N-terminal part.
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View Article Onlinewhat extent agonist activity is retained upon Ala / Alau
replacement at position 2. The synthesis of GLP-1[Au]2 (3) was
readily achieved using standard solid phase synthesis with N-
Fmoc protected amino acids and succinimidyl-[(2S)-2-azido-
propyl]carbamate for ureido insertion.27 The agonistic activity of
the oligomer was determined in vitro using HEK293 cells
transfected with GLP-1R (Table 1) and bTC6 cells which express
GLP-1R endogenously (see ESI, Table S1†) by measuring the
receptor-mediated cAMP production in the presence of the
agonist. The results show that 3 is active with an EC50 of 2.7 pM
which is equivalent to that of GLP-1–NH2 (2) (3.2 pM). An
agonist radioligand assay was then used to further evaluate the
interaction of 3 with GLP-1R (Table 1). The data show that 3
binds GLP-1 in the nM range (IC50¼ 32 nM) but less tightly than
2 (2.4 nM). It is noteworthy that despite a 10-fold reduction in
binding eﬃcacy, the agonist activity (EC50) of 3 is largely
retained.
To validate our hypothesis that the additional NH of urea is
involved in the binding, we synthesized two new analogues in
which the urea NH in 3was replaced by either a CH2 group or an
oxygen (O) to generate g-amino-acid- and carbamate-containing
peptides GLP-1[gA]2 (4) and GLP-1[Ac]2 (5). These modications
cause a 5- to 10-fold loss in potency relative to 3. Attempts to
vary the nature of the side chain of the ureido unit in 3 (e.g. Valu,9874 | Chem. Sci., 2019, 10, 9872–9879Ileu, Pheu, Gluu, Seru, etc.) led to analogues with signicantly
reduced biological activity (see the ESI, Table S1†). These results
are consistent with those of the previously reported SAR
studies28 and with the model presented in Fig. 2b which shows
the limited space available in the pocket around the ureido
residue to accommodate larger side chains. Exchanging the
methyl side chain for an isopropyl (Valu, 8), removing the
methyl side chain (Glyu, 7) and shiing the methyl group of the
ureido residue from the b- to the a-carbon (Alaua, 6) were also
tried, but again with a loss of potency (>1000-, 5- and 24-fold
respectively), demonstrating that the methyl side chain on the
b-carbon is optimal to stabilize GLP-1R in the fully active state.
We then investigated the scope of this approach by incor-
porating the Alau2 modication in exenatide (9) and lixisenatide
(12), two GLP-1 analogues currently approved by the FDA for the
treatment of T2DM. More precisely, Alau was introduced in the
Leu14 analogues Ex4L (10) and LixiL (13), which are less
susceptible to oxidation and show similar potency.29 As before,
the resulting monosubstituted ureido analogues 11 and 14
displayed potent agonist activities, comparable to that of the
native peptide in both cases. Binding studies were also per-
formed on exenatide (9) and the ureidopeptide analogue 11 and
again a ten-fold diﬀerence in binding (IC50 of 0.18 and 1.9 nM,
respectively) was observed, consistent with the results obtained
for 3 (Table 1).Mouse plasma and in vivo studies in mice
To further evaluate the potential benets of the Ala2/ Alau2
replacement in GLP-1R activating peptides, a comparative
stability study in mouse plasma was conducted on compounds
2–14. Solutions of peptides, ureidopeptides or oligomers were
treated with mouse plasma and their stabilities were assessed.
Remarkably, in all cases, the introduction of the ureido residue
in position 2 resulted in a substantially longer in vitro half-life.
Ex4L[Au]2 (11) was found to persist for signicantly longer in the
serum (half-life of 9.3 hours) than Ex4L (10) for which a half-life
of 5.4 hours was measured. So by replacing only one amino acid
with a ureido alanine (Alau) we increased the half-life in mouse
plasma by 1.7-fold with no impact on the EC50. For the next step,
we conducted a series of experiments in mice to see if this
improvement could be translated in vivo. Healthy mice were
fasted for 6 hours and acutely treated with 1 mg (10 nmol kg1)
of GLP-1 analogues injected i.v. 3, 6, and 9 hours before per-
forming an intra-peritoneal glucose tolerance test (IPGTT)
(Fig. 3).
When the IPGTT is performed 3 hours aer the adminis-
tration of the GLP-1 analogues or the vehicle, we observe
a strong control over blood glucose for both exenatide (9) and
Ex4L[Au]2 (11) compared to the vehicle, with a signicant
decrease even at T0 before the administration of glucose
(Fig. 3a). Interestingly, aer 6 hours, we can already observe that
exenatide has partially lost its eﬃcacy while 11 is still fully active
(Fig. 3b). In the experiment shown in Fig. 3c, glucose was
administered 9 hours aer injection of ureidopeptides 11 and
14 which were directly compared to the lixisenatide analogue
LixiL (13) as a reference. Lixisenatide is a once daily GLP-1RThis journal is © The Royal Society of Chemistry 2019
Fig. 3 Pharmacodynamic studies in healthy mice (C57BL/6J, male, 20–25 g). Dosage: 1 mg per mouse (10 nmol kg1) i.v. Formulation: 4 mg mL1
in PBS 1. IPGTT: glucose 2 g kg1 i.p. at T0. (a) IPGTT 3 h after dosing: trace and AUC. Fasted 6 h. (b) IPGTT 6 h after dosing: trace and AUC.
Fasted 6 h. (c) IPGTT 9 h after dosing: trace and AUC. Fasted 9 h. (d) Fasted blood glucose before and after dosing and before the IPGTT 9 h in (c).
Data are mean SEM (n ¼ 6). Statistics by two-way ANOVA and Bonferroni post-test: *p < 0.05, **p < 0.01, ***p < 0.001, comparing the vehicle
to oligomers; one way ANOVAwith Dunnett's multiple comparison test: #p < 0.05, ##p < 0.01, ###p < 0.001, comparing the vehicle to oligomers.
IPGTT: intraperitoneal glucose tolerance test; AUC: area under the curve; i.v.: intra venous; i.p.: intra peritoneal.
Fig. 4 Dose–response relationships of exenatide (9), LixiL (13) and
their putative ureidopeptides Ex4L[Au]2 (11) and LixiL[Au]2 (14) in healthy
mice (C57BL/6J, male, 25–30 g). Dose response relationships from
IPGTT results shown in the ESI, Fig. S4†, 3-parameter ﬁts of area-
under-curve values (n ¼ 8). Dosage and formulation: 0.01 to 10 nmol
kg1 in 100 mL saline i.p. Fasted 4 h prior to agonist administration.
IPGTT (2 mmol kg1 glucose) performed 6 hours after administration
of indicated agonist dose in lean C57Bl/6 mice. Data are mean  SEM.
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View Article Onlineagonist with an increased binding aﬃnity to the receptor and
a prolonged half-life in vivo compared to exenatide.11 In this
case, LixiL (13) shows a small glucose-lowering eﬀect 9 hours
aer treatment, compared to the vehicle. In contrast, 11 and 14
demonstrated a strong ability to control blood glucose levels
with almost no increase in the IPGTT curves. These results are
in accordance with the fasting blood glucose curves covering the
9 hours preceding the IPGTT where we can see that the eﬀect of
the ureidopeptides 11 and 14 is maintained while in the case of
13 the blood glucose tends to increase aer 4 hours (Fig. 3d). In
order to quantify the improvements of the ureidopeptides in
vivo, a dose–response relationship study was conducted to
determine the ED50 of 9, 11, 13 and 14 (Fig. 4). Mice were treated
with diﬀerent doses of analogues and IPGTTs were performed
aer 6 h. From these results dose–response curves were ob-
tained and in vivo ED50 values were calculated. Exenatide (9) and
LixiL (13) showed ED50 values of 2.4 and 2.2 nM, respectively,
while the ureidopeptide analogues Ex4L[Au]2 (11) and LixiL[Au]2
(14) demonstrated a ve-fold improvement with ED50 values of
0.48 and 0.46 nM, respectively.
These studies clearly show that introducing a ureido alanine
at position 2 of a GLP-1 analogue can signicantly prolong its
eﬃcacy in vivo.
In another study in healthy mice, liraglutide (15) and ure-
idopeptides 11 and 14 were administered with the same dose as
in the IPGTTs and their fed blood glucose was followed over 30
hours to assess their maximum duration of action (Fig. 5a).
Interestingly, all three compounds had similar fed blood
glucose curves which suggested that 11 and 14 have a similar
lasting period to liraglutide. Liraglutide is a long acting FDA-
approved GLP-1 analogue with a fatty acid chain attached on
Lys26 to increase albumin binding and is used as a once daily
treatment (Table 1).11 To further validate the potential relevance
of ureido analogues of GLP-1 for treating T2DM, we nextThis journal is © The Royal Society of Chemistry 2019conducted a study on diabetic db/db mice. The mice were
treated via the subcutaneous route, once daily over 15 days with
11 (25 nmol kg1) or with liraglutide (25 nmol kg1). A number
of parameters were measured during the experiment such as
body weight, plasma insulin, fed blood glucose, and glycated
haemoglobin (HbA1c) levels (Fig. 5 and the ESI†). Fed blood
glucose showed similar reductions as in healthy mice, con-
rming the results while suggesting that 11 might be even
better than liraglutide (Fig. 5b). However liraglutide tends to
have a better control on the fasted blood glucose as demon-
strated by the blood glucose at T0 in the IPGTT aer 6 hours of
administration of the GLP-1 analogues, which is reected in
a better AUC (Fig. 5c). Interestingly, treatment with 11 led toChem. Sci., 2019, 10, 9872–9879 | 9875
Fig. 5 Comparative pharmacodynamics of Ex4L[Au]2 (11), LixiL[Au]2 (14) and liraglutide (15) in mice. (a) Fed blood glucose in healthy mice (C57BL/
6J, male, 20–25 g): trace and AUC (n ¼ 6). Dosage: 1 mg per mouse (10 nmol kg1) i.v. Formulation: 4 mg mL1 in PBS 1. (b–e) Study on db/db
mice treated over 15 days (n¼ 10). Dosage: 100 mg kg1 (25 nmol kg1) s.c. once a day (n¼ 10). Formulation: 20 mg mL1 in PBS 1. (b) Fed blood
glucose before and after treatment on day 7: trace and AUC. (c) OGTT 6 hours after dosing on day 12: trace and AUC. OGTT: glucose 1 g kg1 i.p.
at T0. (d) Body weight across the study. (e) Plasma insulin before and after the OGTT on day 12. Data are mean  SEM. Statistics by two-way
ANOVA and Bonferroni post-test: *p < 0.05, **p < 0.01, ***p < 0.001, comparing the vehicle to oligomers; one way ANOVA with Dunnett's
multiple comparison test: #p < 0.05, ##p < 0.01, ###p < 0.001, comparing the vehicle to oligomers. IPGTT: intraperitoneal glucose tolerance test;
AUC: area under the curve; i.v.: intra venous; s.c.: subcutaneous; i.p.: intra peritoneal.
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View Article Onlinea signicant increase in insulin production compared to that
with the vehicle and is superior to liraglutide (Fig. 5e).
Overall, the data obtained in this study showed that 11 and
liraglutide have similar activities in the db/db mouse model.
This is remarkable considering that liraglutide's longer lasting
period is due to it binding to serum albumin through its lipid
side chain, while it is unlikely that Ex4L[Au]2 11 binds to
albumin to the same extent.Pharmacokinetic studies
In light of these interesting results, we sought to understand the
underlying causes of such improvements of exenatide and lix-
isenatide by the substitution of one amino acid over 39 and 45,
respectively. Our hypothesis was that the cleavage between posi-
tions 1 and 2 of exenatide (9) and lixisenatide (12) was a deter-
mining factor for their in vivo half-life17 and, as we managed to
improve the proteolytic stability of the peptides in vitro, as
demonstrated by the increasedmouse plasma stability, this would
be reected in improved in vivo half-life proles. To validate this
hypothesis, we conducted pharmacokinetic studies on healthy
mice with Ex4L (10) and Ex4L[Alau]2 (11). Surprisingly, no signi-
cant diﬀerence was observed between the two analogues (ESI†).GLP-1R biased signalling and traﬃcking
As it was diﬃcult to explain the full extent of the pharmacody-
namic eﬀects solely from the in vitro plasma stability, we sought
other hypotheses that would help to fully account for our in vivo
results. It has been reported in recent studies that modifying
GLP-1 and GLP-1-related peptides can lead to the selective9876 | Chem. Sci., 2019, 10, 9872–9879enhancement of particular intracellular signalling pathways,
usually referred to as “signal bias”.14,30,31 In one example, exe-
natide-derived peptides with amino acid substitutions close to
the N-terminus (such as “exenatide-F1”) showed reduced
recruitment of b-arrestin whilst maintaining full agonist
behaviour for G protein-dependent cAMP signalling;30 further-
more, these compounds displayed markedly reduced tenden-
cies to induce GLP-1R endocytosis. These properties allowed for
enhancement of insulin secretion via a combination of reduced
GLP-1R desensitisation and preservation of surface GLP-1Rs
available to the extracellular agonist. We hypothesized that
a similar phenomenon may apply to the ureidopeptides
described herein which also contain modications at the N-
terminal portion of exenatide. Therefore, signal bias and eﬀects
on GLP-1R endocytosis were assessed for Ex4L (10), LixiL (13)
and their ureidopeptide analogues 11 and 14, respectively
(Fig. 6). Interestingly, in both cases, the recruitment of b-
arrestin to GLP-1Rs was selectively diminished, as shown in
Fig. 6a, with quantication of bias via the operational model32
conrming a strong preference for cAMP signalling (Fig. 7).
Moreover, endocytosis of the GLP-1R was noticeably reduced
aer treatment with ureido- compared to non-ureido-peptides,
as assessed by confocal microscopy in INS-1 832/3 beta cells
with endogenous GLP-1R knocked out by CRISPR/Cas9,33
modied to express SNAP-tagged human GLP-1R which was
surface-labelled prior to agonist treatment (Fig. 6b and the ESI,
Fig. S7†). The reduced residence time of 11 suggested by its
increased IC50, in conjunction with this reduced internalisation
propensity, is compatible with the previously described rela-
tionship between agonist binding kinetics and GLP-1RThis journal is © The Royal Society of Chemistry 2019
Fig. 6 GLP-1R biased signalling and traﬃcking studies. (a) Cyclic AMP (cAMP) and b-arrestin-2 (barr2) responses in PathHunter CHO–GLP-1R
cells, 30 min stimulation, all ligands and pathways run in parallel, results normalized to global maximum responses (cAMP) or GLP-1–NH2 (2)
maximal response (barr2), 4-parameter ﬁt shown, n¼ 5 independent experiments. (b) Confocal analysis of SNAP-GLP-1R internalization in SNAP-
GLP-1R-expressing INS-1 832/3 cells labeled with SNAP-Surface 549 probe (red) for 30 min and then stimulated with 10 nM of the indicated
ligand for a further 30 min. Nuclei (DAPI), blue; size bars, 10 mm. (c) Insulin secretion in INS-1 832/3 cells, 16 h stimulation at 11 mM glucose, all
ligands run in parallel, normalised to basal response in each assay, 3-parameter ﬁt shown, n ¼ 5 independent experiments, Emax compared by 2-
way repeat measures ANOVA with Tukey's test.
Fig. 7 GLP-1R biased signalling. Signal bias calculated from the data
shown in Fig. 6a, expressed relative to GLP-1–NH2 (2), determined
using a modiﬁed form of the operational model (see Methods for
details†), and 1-way randomised block ANOVA with Tukey's test of
diﬀerence between Log R values for cAMP vs. b-arrestin-2 responses
for each ligand.
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View Article Onlineendocytosis.30 In keeping with the cellular mechanism
described by Jones et al.,30 both exenatide and lixisenatide
ureidopeptide analogues 11 and 14 showed signicantly
increased insulin release (Fig. 6c) assessed in vitro, mirroring
our previous observations in the db/db mouse study (Fig. 5e).
The combination of reduced b-arrestin recruitment and GLP-1R
endocytosis, associated with enhanced insulin release in vitro
and in vivo, is remarkably consistent with the characteristics of
exenatide-F1,30 suggesting a similar mechanism of action.
Moreover, we note similarities with another biased GLP-1R
agonist, exendin-P5,31 which shows selectively increased
coupling to cAMP signalling in spite of somewhat reduced
binding aﬃnity versus exenatide.34 Further investigations are
required to fully understand the mechanism of action of these
analogues and will be reported in due course.This journal is © The Royal Society of Chemistry 2019Conclusions
In summary, we rationalized the design of singly substituted
ureido analogues of GLP-1 using molecular modelling, showing
that the replacement of the amino acid in position 2 of GLP-1 with
an ureido alanine (Alau) does not impair its agonist activity.
Moreover, the same modication introduced in exenatide and
lixisenatide considerably prolongs their eﬃcacy in vivo with
a signicant reduction of blood glucose levels observed over at
least 9 hours in healthy mice. Additionally, we have shown that
this monosubstituted analogue is also active in db/dbmice, a type
2 diabetes mellitus animal model, giving similar result to the FDA
approved liraglutide. A key mechanism for the improved biolog-
ical eﬃcacy of these compounds appears to be the enhancement
of insulin secretion via eﬀects on signal bias and GLP-1R traf-
cking on pancreatic b-cells. Indeed, introducing a ureido residue
at position 2 of exenatide and lixisenatide preserves their eﬃcacy
while diminishing their aﬃnity, which may result in a shorter
residence time in the receptor and therefore reduced endocytosis
of the GLP-1 receptor. Further studies are required to fully eluci-
date this mechanism.
All in all, this study demonstrates and validates the approach
of substituting simple a-amino acids with their ureido coun-
terparts to improve the pharmacological properties of biologi-
cally relevant peptides. The evaluation of replacing multiple
amino acids to generate ureidopeptides with multiple isolated
ureido residues and/or the combination of this approach with
other strategies like acylation with fatty acids or combination
with oligoureas to generate ureidopeptide–oligourea hybrids
will be reported in due course.Chem. Sci., 2019, 10, 9872–9879 | 9877
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